Idiopathic Pulmonary Hypertension  >>  Tracleer (bosentan)  >>  Phase N/A
Welcome,         Profile    Billing    Logout  

5 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Tracleer (bosentan) / J&J, Roche
PARBO, NCT01721564: Bosentan and Pulmonary Endothelial Function

Completed
N/A
8
RoW
Bosentan
Prof David S Celermajer
Pulmonary Arterial Hypertension
05/09
12/09
NCT00909337: Early Therapy of Pulmonary Arterial Hypertension

Completed
N/A
10
Europe
Bosentan, Tracleer
Medical University of Graz, Actelion
Pulmonary Hypertension, Systemic Sclerosis
06/10
06/10
Aspire, NCT01266265: Study of Incidence of Respiratory Tract AEs in Patients Treated With Tyvaso® Compared to Other FDA Approved PAH Therapies

Completed
N/A
1333
US
inhaled prostacyclin, treprostinil, iloprost, Ventavis, prostacyclin, epoprostenol sodium, Flolan, subcutaneous and intravenous prostacyclin, treprostinil , Remodulin, oral ERA, bosentan, Tracleer, ambrisentan, Letairis, oral PDE5 inhibitors, sildenafil, Revatio, tadalafil, Adcirca
United Therapeutics
Pulmonary Arterial Hypertension
12/14
12/14
NCT01247116: First-line Bosentan and Sildenafil Combination Therapy for Pulmonary Arterial Hypertension

Completed
N/A
12
Canada
University of Calgary, Actelion
Hypertension, Pulmonary
12/15
12/15
PAH QuERI Ext, NCT01389206: Pulmonary Arterial Hypertension Quality Enhancement Research Initiative Extension Program

Completed
N/A
797
US
observational study with patients treated with Tracleer, Ventavis, Veletri, Opsumit and/or Uptravi
Actelion, Canadian Heart Research Centre
Pulmonary Arterial Hypertension
04/18
04/18

Download Options